Summary：Concern Grows as Health Ministry Requires Prescriptions for High‑Alcohol Drugs **Introduction** PuConcern Grows as Health Ministry Requires Prescriptions for High‑Alcohol Drugs
**Introduction**
Public health officials are sounding the alarm after the Ministry of Health announced a new rule that will mandate prescriptions for all medications containing high concentrations of alcohol. The measure, set to take effect next quarter, aims to curb misuse and accidental overdoses linked to readily available over‑the‑counter products such as cough syrups, topical antiseptics, and certain herbal tonics. Stakeholders ranging from pharmacists to patient advocacy groups are weighing the potential benefits against concerns about accessibility and cost.
**Key Developments**
The directive, published in the official gazette on May 12, classifies any drug with an alcohol content exceeding 20 % by volume as a “high‑alcohol medication.” Under the new regulation, these products will be moved from the general sales shelf to the prescription‑only category, requiring a doctor’s authorization before purchase. The ministry cited a rise in emergency department visits tied to intentional ingestion of alcohol‑laden syrups, particularly among adolescents and individuals with substance‑use disorders. To enforce the change, the agency will partner with the Pharmaceutical Board to update labeling, conduct pharmacy audits, and launch a public awareness campaign highlighting the risks of unsupervised consumption.
**Industry Analysis**
Industry analysts warn that the prescription barrier could disrupt supply chains for manufacturers that rely on high‑volume retail sales. “Moving these products behind the counter will inevitably reduce turnover for small‑scale producers who lack the infrastructure to handle prescription processing,” said Laura Mendoza, senior analyst at PharmaInsight. Conversely, some experts argue that the shift may spur innovation, prompting firms to develop lower‑alcohol alternatives or non‑alcoholic formulations that retain therapeutic efficacy. Retail pharmacists anticipate an initial workload increase as they verify prescriptions, but many believe the long‑term payoff—fewer alcohol‑related poisonings—will justify the adjustment.
**Future Outlook**
The ministry plans to review the policy’s impact after six months, using data from poison control centers and hospital admissions to assess whether the prescription requirement has curbed misuse. If successful, officials may consider extending similar controls to other volatile substances found in consumer health products. Stakeholders are urging the government to accompany the rule with subsidies or reimbursement mechanisms for patients who rely on high‑alcohol drugs for legitimate medical reasons, ensuring that public safety does not come
